640 related articles for article (PubMed ID: 29682980)
1. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
2. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
5. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
7. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
[TBL] [Abstract][Full Text] [Related]
8. Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies.
Chen X; Li N; Weng J; Du X
Front Cell Dev Biol; 2020; 8():617466. PubMed ID: 33644035
[TBL] [Abstract][Full Text] [Related]
9. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cell senescence in haematological malignancies.
Plakhova N; Panagopoulos V; Vandyke K; Zannettino ACW; Mrozik KM
Cancer Metastasis Rev; 2023 Mar; 42(1):277-296. PubMed ID: 36622509
[TBL] [Abstract][Full Text] [Related]
12. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
13. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
[TBL] [Abstract][Full Text] [Related]
14. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
15. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.
Fei C; Zhao Y; Guo J; Gu S; Li X; Chang C
Eur J Haematol; 2014 Dec; 93(6):476-86. PubMed ID: 24889123
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.
Kim M; Hwang S; Park K; Kim SY; Lee YK; Lee DS
PLoS One; 2015; 10(3):e0120602. PubMed ID: 25803272
[TBL] [Abstract][Full Text] [Related]
18. Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation.
Shi L; Zhao Y; Fei C; Guo J; Jia Y; Wu D; Wu L; Chang C
Aging (Albany NY); 2019 Nov; 11(21):9626-9642. PubMed ID: 31727865
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zhao Y; Wu D; Fei C; Guo J; Gu S; Zhu Y; Xu F; Zhang Z; Wu L; Li X; Chang C
Haematologica; 2015 Feb; 100(2):194-204. PubMed ID: 25361944
[TBL] [Abstract][Full Text] [Related]
20. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS
Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
